Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study

Summary

Early randomized double-blind placebo-controlled study assessing once-weekly pemvidutide in adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease.

Limitations

Small phase 1b sample, short primary treatment period and surrogate endpoints limit certainty. Histological outcomes, long-term safety and patient-important liver outcomes were not established.

Linked peptides

• Pemvidutide